Biomerieux SA
PAR:BIM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biomerieux SA
PAR:BIM
|
FR |
Intrinsic Value
The intrinsic value of Biomerieux SA (BIM) under the Base Case is 114.72 EUR per share.
Compared with the current market price of 89.2 EUR, the stock appears
Undervalued by 22% .
The intrinsic value is calculated using the DCF method. The model assumes net margin rises from 9.8% last year to 14% by 2031, above its five-year average of 12%. If net margin stayed at its five-year average of 12%, the estimate would be about €99.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Biomerieux Does
bioMérieux makes laboratory tests that help doctors and companies find microbes and understand whether a sample is safe. Its products include testing instruments, disposable reagents, software, and service contracts. In hospitals and public labs, these tests are used to identify infections and guide treatment decisions.
- Headquarters
- France FR
- Employees
- 14 894
- IPO date
- Jun 7, 2004
Biomerieux has no economic moat
Hospitals, laboratories and industrial customers can choose among competing diagnostic systems, and bioMérieux’s products do not become more valuable just because more customers use them. Its strong presence in some areas does not prevent rivals from competing for buyers or guarantee that customers will pay more for its name alone.
Read the full moat analysis
Earnings Waterfall
Biomerieux SA
The intrinsic value for Biomerieux SA (BIM) under the Base Case is 114.72 EUR.
Compared with the current market price of 89.2 EUR, the stock appears Undervalued by 22% .